Andrea Franson, MD, discusses the mechanism of action of tovorafenib and its emerging role within the evolving treatment paradigm for pLGG.
Navigating Second-Line Treatment in Pediatric Low-Grade Glioma
Experts discuss ongoing research and factors driving treatment selection in second-line pediatric low-grade glioma.
Andrea Franson, MD, MS, discusses safety data on tovorafenib in relapsed or refractory pediatric low-grade glioma from the FIREFLY-1 trial.
Cassie Kline, MD, MAS, discusses data from the phase 2 FIREFLY-1 trial of tovorafenib in relapsed/refractory pediatric low-grade glioma.
Mohamed Abdelbaki, MD, discusses second-line targeted therapy options for pediatric low-grade glioma.
Tovorafenib produced deep, durable responses in pLGG, with long treatment-free intervals and minimal tumor rebound after therapy.
Dr Kline discusses longer-term efficacy data from the FIREFLY-1 study of tovorafenib in patients with relapsed/refractory pediatric low-grade glioma.
Cassie Kline, MD, MAS, discusses 3-year follow-up data with tovorafenib in patients with pediatric low-grade glioma from FIREFLY-1.
Advertisement
Advertisement
Trending on OncLive
1
FDA Approves Daraxonrasib for Metastatic Pancreatic Ductal Adenocarcinoma
2
Dr Reiss Binder on the FDA Approval of Daraxonrasib for Metastatic PDAC
3
ASCO Issues Warning Regarding Ifosfamide Shortage for Cancer Care
4
Dr Ayanambakkam on the Safety of Darlifarnib Plus Cabozantinib in RCC KD
5